Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03077672 · ClinicalTrials.gov registry record
Mitochondrial DNA as a Biomarker of Sepsis Severity
A clinical trial, sponsored by Weill Medical College of Cornell University.
- Completed
- Registry status
- 1,304
- Enrollment target
NCT03077672: Completed study, sponsored by Weill Medical College of Cornell University.
NCT03077672 is a clinical trial that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 1,304 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03077672 has completed, sponsored by Weill Medical College of Cornell University.
- COMPLETED
- Registry status
- 1,304 participants
- Enrollment target
Study Summary
Mitochondria are organelles (a specialized subunit of a cell) responsible for providing cells with energy. For reasons not yet understood, mitochondria will release their DNA into blood in response to cellular injury or cell death. With a simple blood draw, investigators can measure the amount of mitochondrial DNA in a patient's blood. The investigators' hypothesis, is that mitochondrial DNA can be used as a surrogate marker of cellular injury to predict patient outcomes. The investigators intend to test their hypothesis by measuring mitochondrial DNA in adult patients presenting to the Emergency Department with sepsis (a life-threatening condition due to an infection) and observing their hospital course.
Primary Outcome
All-Cause
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,304 participants |
| Start Date | 2017-02-10 |
| Est. Completion | 2020-12-22 |
What the finished NCT03077672 record still lists
NCT03077672 is an observational study that tracks outcomes without assigning an intervention. Its 1,304 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT03077672 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03077672 about?
NCT03077672 is a clinical study titled "Mitochondrial DNA as a Biomarker of Sepsis Severity". Mitochondria are organelles (a specialized subunit of a cell) responsible for providing cells with energy. For reasons not yet understood, mitochondria will release their DNA into blood in response to cellular injury or cell death. With a simple blood draw, investigators can measure the amount of m...
What is the current status of trial NCT03077672?
This trial is currently completed. The enrollment target is 1,304 participants. The study started on 2017-02-10. Estimated completion is 2020-12-22.
Who is sponsoring clinical trial NCT03077672?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04171323 · 1,305 participants · NA
The Active Mind Trial: An Adaptive Randomized Trial to Improve Function and Delay Dementia
- NCT06517901 · 1,306 participants · NA
Fusion or Cognitive Ultrasound-guided Biopsy to Detect Prostate Cancer
- NCT04474223 · 1,300 participants · Phase 3
Surveillance and Treatment to Prevent Fetal Atrioventricular Block Likely to Occur Quickly (STOP BLOQ)
- NCT04792684 · 1,300 participants
Collection of Samples USOPTIVAL Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI